NCT02571192

A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose

A Phase 1, Open-label Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of [14C]-SHP626 Following a Single Oral Dose in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Mirum Pharmaceuticals, Inc. · Industry
• Sex: Male
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine how SHP626 is absorbed and excreted from the body in healthy males.

Conditions

• Non-Alcoholic Steatohepatitis

Interventions

Type	Name	Description
DRUG	SHP626	single oral dose 50mg SHP626 with approximately 5.95 μCi RAD
RADIATION	5.95 μCi RAD

Timeline

• Start date: 2015-10-01
• Primary completion: 2015-10-01
• Completion: 2015-10-01
• First posted: 2015-10-08
• Last updated: 2019-05-01

Locations

1 site across 1 country: United States